Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- US stock futures dip as oil breaches $100 mark for the first time since mid-year
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Insulet Corporation (PODD) PT Raised to $310 at BTIG
February 21, 2025 5:09 AM ESTBTIG analyst Marie Thibault raised the price target on Insulet Corporation (NASDAQ: PODD) to $310.00 (from $300.00) while maintaining a Buy rating.
The analyst comments "Insulet reported Q4 revenue of $597.5M (+17% y/y), beating the consensus estimate of $583M and above the top end of the ~$571-$586M guidance range. U.S. Omnipod revenue of $443.7M (+12.4% y/y) was ~$7.5M above consensus of $436.3M while International Omnipod revenue of $142.0 (+33.1% cc y/ y) was ~$2M higher than consensus. Drug Delivery sales were $11.8M (cons. $6.5M). Type 2 patients were >30% of new U.S. starts in Q4... More
